Precigen Shares Rise on Positive Long-Term Follow-Up Data From Papzimeos

Dow Jones

Oct 13, 2025

By Chris Wack

Precigen shares were up 6%, to $3.32, in premarket trading after the company said it saw positive long-term follow-up data for Papzimeos for treatment of adults with recurrent respiratory papillomatosis.

Papzimeos was granted full approval by the Food and Drug Administration in August.

The biopharmaceutical company said Papzimeos approval was supported by results from a study that met its primary safety and pre-specified primary efficacy endpoints. Papzimeos was well tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2.

The Germantown, Md., company said 51%, or 18 out of 35, of study patients achieved complete response, requiring no surgeries in the 12-month period after treatment with Papzimeos.

Precigen said prolonged reduction in the requirement for surgical intervention to manage RRP was observed throughout long-term follow-up of evaluable study patients compared to the year prior to treatment.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

October 13, 2025 07:54 ET (11:54 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2575334405"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575334405\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575334405?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 19:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575334405","market":"fut","top_or_hot":-1,"title":"Precigen Shares Rise on Positive Long-Term Follow-Up Data From Papzimeos","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/PGEN\">Precigen</a> shares were up 6%, to $3.32, in premarket trading after the company said it saw positive long-term follow-up data for Papzimeos for treatment of adults with recurrent respiratory papillomatosis. \n</p>\n<p>\n  Papzimeos was granted full approval by the Food and Drug Administration in August. \n</p>\n<p>\n  The biopharmaceutical company said Papzimeos approval was supported by results from a study that met its primary safety and pre-specified primary efficacy endpoints. Papzimeos was well tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2. \n</p>\n<p>\n  The Germantown, Md., company said 51%, or 18 out of 35, of study patients achieved complete response, requiring no surgeries in the 12-month period after treatment with Papzimeos. \n</p>\n<p>\n  Precigen said prolonged reduction in the requirement for surgical intervention to manage RRP was observed throughout long-term follow-up of evaluable study patients compared to the year prior to treatment. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 13, 2025 07:54 ET (11:54 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Precigen Shares Rise on Positive Long-Term Follow-Up Data From Papzimeos</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrecigen Shares Rise on Positive Long-Term Follow-Up Data From Papzimeos\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-13 19:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/PGEN\">Precigen</a> shares were up 6%, to $3.32, in premarket trading after the company said it saw positive long-term follow-up data for Papzimeos for treatment of adults with recurrent respiratory papillomatosis. \n</p>\n<p>\n  Papzimeos was granted full approval by the Food and Drug Administration in August. \n</p>\n<p>\n  The biopharmaceutical company said Papzimeos approval was supported by results from a study that met its primary safety and pre-specified primary efficacy endpoints. Papzimeos was well tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2. \n</p>\n<p>\n  The Germantown, Md., company said 51%, or 18 out of 35, of study patients achieved complete response, requiring no surgeries in the 12-month period after treatment with Papzimeos. \n</p>\n<p>\n  Precigen said prolonged reduction in the requirement for surgical intervention to manage RRP was observed throughout long-term follow-up of evaluable study patients compared to the year prior to treatment. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 13, 2025 07:54 ET (11:54 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PGEN","symbol_name":"Precigen","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2575334405","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575334405","pubTimestamp":1760356440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Precigen shares were up 6%, to $3.32, in premarket trading after the company said it saw positive long-term follow-up data for Papzimeos for treatment of adults with recurrent respiratory papillomatosis.Papzimeos was granted full approval by the Food and Drug Administration in August.The biopharmaceutical company said Papzimeos approval was supported by results from a study that met its primary safety and pre-specified primary efficacy endpoints. Papzimeos was well tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2.The Germantown, Md., company said 51%, or 18 out of 35, of study patients achieved complete response, requiring no surgeries in the 12-month period after treatment with Papzimeos.Precigen said prolonged reduction in the requirement for surgical intervention to manage RRP was observed throughout long-term follow-up of evaluable study patients compared to the year prior to treatment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PGEN":"Precigen","BK4139":"生物科技"},"translate_title":"Precigen股价因Papzimeos积极的长期随访数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGEN":1.5},"content_text":"By Chris Wack \n\n\n \n\n\nPrecigen shares were up 6%, to $3.32, in premarket trading after the company said it saw positive long-term follow-up data for Papzimeos for treatment of adults with recurrent respiratory papillomatosis. \n\n\n  Papzimeos was granted full approval by the Food and Drug Administration in August. \n\n\n  The biopharmaceutical company said Papzimeos approval was supported by results from a study that met its primary safety and pre-specified primary efficacy endpoints. Papzimeos was well tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2. \n\n\n  The Germantown, Md., company said 51%, or 18 out of 35, of study patients achieved complete response, requiring no surgeries in the 12-month period after treatment with Papzimeos. \n\n\n  Precigen said prolonged reduction in the requirement for surgical intervention to manage RRP was observed throughout long-term follow-up of evaluable study patients compared to the year prior to treatment. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 13, 2025 07:54 ET (11:54 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}